[3.2.0] Heterocyclic compounds and methods of using the same

Details [3.2.0] Heterocyclic compounds and methods of using the same [3.2.0] Heterocyclic compounds and methods of using the same

2007-10-02

2007-10-02

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S453000

Reexamination Certificate

active

11118260

ABSTRACT:
Compounds of Formulae I-VI and derivatives thereof having anti-cancer, anti-inflammatory, and anti-microbial properties and to compositions that include one or more of compounds and their derivatives or analogs having anti-cancer, anti-inflammatory and anti-microbial properties are disclosed. Pharmaceutical compositions comprising such compounds and methods of treating cancer, inflammatory conditions, and microbial infections with the disclosed compounds or the disclosed pharmaceutical compositions are also disclosed.

REFERENCES:
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5576012 (1996-11-01), Bauer et al.
patent: 5601845 (1997-02-01), Buxton et al.
patent: 5641515 (1997-06-01), Ramtoola
patent: 5653987 (1997-08-01), Modi et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5667809 (1997-09-01), Trevino et al.
patent: 5683676 (1997-11-01), Akehurst et al.
patent: 5688529 (1997-11-01), Lidgate et al.
patent: 5707615 (1998-01-01), Cardin et al.
patent: 5707641 (1998-01-01), Gertner et al.
patent: 5726181 (1998-03-01), Hausheer et al.
patent: 5733888 (1998-03-01), Carver et al.
patent: 5756764 (1998-05-01), Fenteany et al.
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5886210 (1999-03-01), Rayle et al.
patent: 5922683 (1999-07-01), Or et al.
patent: 6133308 (2000-10-01), Soucy et al.
patent: 6147223 (2000-11-01), Fenteany et al.
patent: 6214862 (2001-04-01), Fenteany et al.
patent: 6294560 (2001-09-01), Soucy et al.
patent: 6335358 (2002-01-01), Fenteany et al.
patent: 6350759 (2002-02-01), Casara et al.
patent: 6458825 (2002-10-01), Fenteany et al.
patent: 6500825 (2002-12-01), Lan et al.
patent: 6506787 (2003-01-01), Fujishita et al.
patent: 6509331 (2003-01-01), Audia et al.
patent: 6566553 (2003-05-01), Soucy et al.
patent: 6645999 (2003-11-01), Schreiber et al.
patent: 6794516 (2004-09-01), Soucy et al.
patent: 6838477 (2005-01-01), Schreiber et al.
patent: 6849743 (2005-02-01), Soucy et al.
patent: 2001/0002391 (2001-05-01), Brand et al.
patent: 2001/0051654 (2001-12-01), Elliott et al.
patent: 2003/0157695 (2003-08-01), Fenical et al.
patent: 2004/0138196 (2004-07-01), Fenical et al.
patent: 2004/0259856 (2004-12-01), Fenical et al.
patent: 2005/0049294 (2005-03-01), Palladino et al.
patent: 2005/0203162 (2005-09-01), Xiao et al.
patent: 2005/0228186 (2005-10-01), Corey
patent: 2005/0239866 (2005-10-01), Fenical et al.
patent: 2006/0008852 (2006-01-01), Fenical et al.
patent: WO96/32105 (1996-10-01), None
patent: WO99/09006 (1999-02-01), None
patent: WO99/15183 (1999-04-01), None
patent: WO 00/23614 (2000-04-01), None
patent: WO 02/47610 (2002-06-01), None
patent: WO 04/043374 (2003-11-01), None
patent: WO 04/071382 (2004-08-01), None
patent: WO 2004071382 (2004-08-01), None
patent: WO 05/002572 (2005-01-01), None
patent: WO 05/003137 (2005-01-01), None
patent: 06/028525 (2005-03-01), None
patent: WO 2005099687 (2005-10-01), None
patent: 06/005551 (2006-01-01), None
patent: 06/060609 (2006-06-01), None
patent: WO 06/060809 (2006-06-01), None
Sapi et al., Collection of Czechoslovak Chemical Communications 1999, 64(2), 190-202.
CAS Abstract attached.
Adams, Julian. “Proteasome inhibitors as new anticancer drugs.”Curr. Opin. Oncol. 14:628 (2002).
Adams, et al., “Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents.”Cancer Res59:2615 (1999).
Adams, J., “The Development of novel targeted therapeutics for treatment of multiple myeloma research roundtable.”European Journal of Haematology70: 263-272. (2003).
Alessandri G, Raju K. & Bullino PM., “Mobilation of capillary endothelium in vitro induced by effectors of angiogenesis in vivo.”Cancer Res. 43(4):1790-7. (1983).
Alm et al., “Effects of Topically Applied PGF2 and its Isopropylester on Normal and Glaucomatous Human Eyes.”Prog. Clin. Biol. Res., 312:447-58 (1989).
Beers, et al.,The Merck Research Laboratories, Whitehouse Station N.J. XP002318189. 1157-1159.
Beers, et al.,The Merck Research Laboratories, Whitehouse Station N.J. XP002318189. 1241-1252.
Bhalla, et al., “High-Dose Mitoxantrone Induces Programmed Cell Death or Apoptosis in Human Myeloid Leukemia Cells.”Blood82:10 pp. 3133-3140 (1993). Eds.
Bicknell, R. J., Claire E. Lewis & Napoleone FE, “Tumour Angiogenesis,” Oxford University Press, New York (Sep. 1, 1997).
Blum, et al., “A New Anticancer Drug with Significant Clinical Activity.”Ann Intern Med80:249 (1974).
Bodart, et al., “Anthrax, MEK and Cancer.”Cell cycle1:10 (2002).
Bradley, et al., “Identification of the Cellular Receptor for Anthrax Toxin.”Nature414:225 (2001).
Bull, A.T. et al., “Search and Discovery Strategies for Biotechnology: the Paradigm Shift.”Microbiol Mol. Biol. Rev. 64:573 (2000).
Carey, Francis.Organic Chemistry, 2d ed., Mcgraw Hill, Inc. New York. pp. 328-331. (1992).
Claverol, et al., “Mapping and Structural Dissection of Human 20 S Proteasome Using Proteomic Approaches.”Mol Cell Proteomics1:567 (2002).
Crane, et al., “A Novel Enantioselective Synthetic Route to Omuralide Analogues with the Potential for Species Selectivity in Proteasome Inhibition.”Organic Letters, 1395-1397. (2001).
Cragg, et al. “Chemical Diversity: a function of biodiversity.”Trends Pharmacol Sci23:404 (2002).
Cusak, et al., “Enhanced Chemosensitivity to CPT-11 with Proteasome Inhibitor PS-341: Implications for Systemic Nuclear Factor-kB Inhibition.”Cancer Res61:3535 (2001).
Decker, et al., “Inhibition of Caspase-3-mediated Poly (ADP-ribose) Polymerase (PARP) Apoptotic Cleavage by Human PARP Autoantibodies and Effect on Cells Undergoing Apoptosis.”J Biol Chem. 275:9043 (2000).
Dick, et al., “Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin.”J Biol Chem. 271:7273 (1996).
“DTP Human Tumor Cell Line Screen.”Screening Services. DPI. Sep. 28, 2005 <http://dtp.nci.nih.gov/branches/btb/ivclsp.html>.
Duesberry, et al., “Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor.”Science280:734 (1998).
Elliott, et al., “Proteasome inhibition: a new anti-inflammatory strategy.”J Mol Med; 81:235-245. (2003).
Elliot, et al., “The Proteasome: A new target for novel drug therapies”,American Journal of Clinical Pathology. 637-646. (2001).
Escuyer, et al., “Anthrax Protective Antigen Interacts with a Specific Receptor on the Surface of CHO-K1 Cells.”Infect Immun59:3381 (1991).
Faulkner, D.J. “Marine Natural Products.”Nat Prod Rep18:1-49 (2001).
Feling, et al. “Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus Salinospora.”Angew. Chem. Int. Ed. 42(3):355-357 (2003).
Fenical, et al. “Marine Microorganisms as a Developing Resource for Drug Discovery.”Pharmaceutical News, 489-494 (2002).
Fenteany G. et al., “Inhibition of Proteasome Activities and Subunit-Specific Amino-Terminal Threonine modification by Lactacystin.”Science, 268, 726-73 (1995).
Fingl, et al., The Pharmaceutical Basis of Therapeutics, 1975.
Folkman, J., “Tumor angiogenesis.”Adv Cancer Res. 43:175-203. (1985).
Folkman, J., “Angiogenesis-dependent diseases.”Semin Oncol, 28, 536-42. (2001).
Fukuchi, et al., “Direct Proteasome inhibition by clasto-lactacystin B-lactone permits the detection of ubiquitinated p21 in ML-1 Cells.”Biochem Biophys Acta1451:206 (1999).
Gale, et al., The Molecular Basis of Antibiotic Action 2ndedition, John Wiley and Sons, London (1981).
Gantt, et al., “Proteasome inhibitors block development of Plasmodium spp.”Antimicrobial Agents and Chemotherapy. 2731-2738. (1998).
Geier, et al., “A Giant Protease with Potential to Substitute for Some Functions of the Proteasome.”Science283:978 (1999).
Goldberg, et al. “Not just research tools—proteasome

Affiliated with

Also associated with

Rating

[3.2.0] Heterocyclic compounds and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with [3.2.0] Heterocyclic compounds and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and [3.2.0] Heterocyclic compounds and methods of using the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3839514